PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial.

By F. Lordick, K. Ott, B. Krause, W. Weber, K. Becker, H. Stein, S. Lorenzen, T. Schuster, H. Wieder, K. Herrmann and 6 more. The Lancet Oncology, 2007

814 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/935871cfa36e0c3756806517aff89cb4d6c1cb33

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Ralph Weissleder
2. M. Pittet

In Pulmonary and Respiratory Medicine

1. Ralph Weissleder
2. Lee Josephson
3. Isaac Koh
4. Vasilis Ntziachristos
5. D. Hanahan
6. Lisa M. Coussens
7. Ron M. A. Heeren
8. Liam A. McDonnell

Citations in the corpus

• Imaging in the era of molecular oncology (2008, methodology): “In the clinic, analysing glucose metabolism by using PET (after administering the probe [ 18 F] fluorodeoxyglucose, which is preferentially taken up by metabolically active cells) is progressively being used as a surrogate for treatment efficacy75,76.”
• A systematic review of the factors affecting accuracy of SUV measurements. (2010, background): “Quantification such as SUV plays a more important role in this scenario; clinical studies to date indicate that most tumors responding to therapy show a 20–40% decrease in SUV early in the treatment course [11–15].”